ARGX

925.7001.73%
KM

Karen Massey

CEO & Executive Director

Ms. Karen Massey serves as CEO & Executive Director of argenx SE since May 6, 2026. She was Chief Operating Officer at argenx SE since March 13, 2023 until May 6, 2026. She has experience in the pharmaceutical and biotechnology industry with an impressive breadth of experience across commercial, product development, corporate strategy & innovation. She served at Genentech (Roche Group), where she most recently served as Senior Vice President of Product Development and Global Clinical Operations. In this capacity, she led a global organization across 24 countries and was accountable for operationalizing over 300 clinical trials within oncology, neuroscience, infectious diseases, immunology and ophthalmology. During her tenure at Genentech, Ms. Massey held various commercial leadership roles across marketing and business operations, including as the Vice President of the Multiple Sclerosis and Neuromyelitis Optica business, leading the team to accelerate the post-launch performance of Ocrevus. Ms. Massey started her biopharmaceutical career in marketing at Pfizer and returned there, as a management consultant at Bain, to take on leadership positions in corporate strategy, sales and as a commercial lead in Latin America. Ms. Massey holds a Bachelor of Economics from the University of Sydney and a Master of Business Administration from the New York University Stern School of Business.

Positions